🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
1.480
-0.020 (-1.33%)
At close: Nov 20, 2026, 4:00 PM EST
1.530
+0.050 (3.38%)
After-hours: Nov 20, 2026, 7:34 PM EST

Lipocine Statistics

Total Valuation

Lipocine has a market cap or net worth of $16.39 million. The enterprise value is -$4.91 million.

Market Cap16.39M
Enterprise Value -4.91M

Important Dates

The last earnings date was Thursday, November 5, 2026, before market open.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

Lipocine has 11.07 million shares outstanding. The number of shares has increased by 34.90% in one year.

Current Share Class 11.07M
Shares Outstanding 11.07M
Shares Change (YoY) +34.90%
Shares Change (QoQ) +0.34%
Owned by Insiders (%) 4.15%
Owned by Institutions (%) 18.91%
Float 9.80M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 4.38
Forward PS 35.44
PB Ratio 0.58
P/TBV Ratio 0.77
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 11.36, with a Debt / Equity ratio of 0.01.

Current Ratio 11.36
Quick Ratio 10.99
Debt / Equity 0.01
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -52.86% and return on invested capital (ROIC) is -35.36%.

Return on Equity (ROE) -52.86%
Return on Assets (ROA) -32.07%
Return on Invested Capital (ROIC) -35.36%
Return on Capital Employed (ROCE) -47.61%
Weighted Average Cost of Capital (WACC) 6.94%
Revenue Per Employee $267,497
Profits Per Employee -$666,483
Employee Count14
Asset Turnover 0.19
Inventory Turnover n/a

Taxes

In the past 12 months, Lipocine has paid $200 in taxes.

Income Tax 200
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -53.89% in the last 52 weeks. The beta is 0.50, so Lipocine's price volatility has been lower than the market average.

Beta (5Y) 0.50
52-Week Price Change -53.89%
50-Day Moving Average 1.78
200-Day Moving Average 3.31
Relative Strength Index (RSI) 40.26
Average Volume (20 Days) 191,283

Short Selling Information

The latest short interest is 325,401, so 2.94% of the outstanding shares have been sold short.

Short Interest 325,401
Short Previous Month 351,433
Short % of Shares Out 2.94%
Short % of Float 3.32%
Short Ratio (days to cover) 0.07

Income Statement

In the last 12 months, Lipocine had revenue of $3.74 million and -$9.33 million in losses. Loss per share was -$1.29.

Revenue3.74M
Gross Profit 3.74M
Operating Income -10.08M
Pretax Income -9.33M
Net Income -9.33M
EBITDA -10.02M
EBIT -10.08M
Loss Per Share -$1.29
Full Income Statement

Balance Sheet

The company has $21.46 million in cash and $161,130 in debt, with a net cash position of $21.29 million or $1.92 per share.

Cash & Cash Equivalents 21.46M
Total Debt 161,130
Net Cash 21.29M
Net Cash Per Share $1.92
Equity (Book Value) 21.16M
Book Value Per Share 2.57
Working Capital 21.08M
Full Balance Sheet

Cash Flow

Operating Cash Flow -10.01M
Capital Expenditures n/a
Depreciation & Amortization 59,090
Net Borrowing n/a
Free Cash Flow -10.01M
FCF Per Share -$0.90
Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -269.06% and -249.16%.

Gross Margin 100.00%
Operating Margin -269.06%
Pretax Margin -249.15%
Profit Margin -249.16%
EBITDA Margin -267.48%
EBIT Margin -269.06%
FCF Margin n/a

Dividends & Yields

Lipocine does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -34.90%
Shareholder Yield -34.90%
Earnings Yield -87.35%
FCF Yield -61.10%

Analyst Forecast

The average price target for Lipocine is $5.00, which is 237.84% higher than the current price. The consensus rating is "Buy".

Price Target $5.00
Price Target Difference 237.84%
Analyst Consensus Buy
Analyst Count 2
Revenue Growth Forecast (3Y) -15.33%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

The last stock split was on May 12, 2023. It was a reverse split with a ratio of 1:17.

Last Split Date May 12, 2023
Split Type Reverse
Split Ratio 1:17

Scores

Lipocine has an Altman Z-Score of -5.37 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -5.37
Piotroski F-Score 1